Core Insights - The 22nd China-ASEAN Expo was held in Nanning, Guangxi, where the gastric cancer pathology diagnostic model V1 was officially launched, marking a breakthrough in the application of artificial intelligence in medical pathology [1][2] - The collaboration between MacAudie and Beijing Yizhuang Intelligent City Research Institute Group represents an innovative practice of cross-industry integration between healthcare and technology [1] Company Overview - MacAudie has three core business segments: intelligent electrical, smart optics, and digital healthcare, showcasing its deep accumulation and development blueprint in energy management, optical innovation, and the full value chain of digital pathology [1] - The gastric cancer pathology diagnostic model V1 consists of two main functional modules: the negative screening model and the classification model, aimed at reducing the workload of pathologists by up to 80% and enhancing diagnostic focus and efficiency [2] Industry Impact - The negative screening model significantly reduces repetitive tasks for pathologists by accurately identifying normal or non-cancerous pathology samples, while the classification model addresses the challenge of precision in identifying common gastric cancer types [2] - This innovation alleviates the shortage of pathology experts and promotes a shift from experience-driven to intelligence-enabled pathology diagnostics [2] Future Developments - The collaboration will continue to focus on the full-process diagnostic needs for gastric cancer, with plans to develop automated diagnostic report generation and ROI intelligent recognition features [3] - The goal is to enhance the model's functionality and expand its application to more tumors and pathology scenarios, contributing to the Healthy China 2030 strategic goal [3]